Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies.
about
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.New therapeutic concepts in prostate cancer.The pre-metastatic niche: is metastasis random?Bisphosphonate therapy in the oncology setting.Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective StudyEffect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws.Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.E2f3 in tumor macrophages promotes lung metastasis.Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.10. Circulating Nucleic Acids as Diagnostic ToolDietary-suppression of hepatic lipogenic enzyme expression in intact male transgenic mice.Sterol-regulatory-element-binding protein 2 and nuclear factor Y control human farnesyl diphosphate synthase expression and affect cell proliferation in hepatoblastoma cells.Variability of the paracrine-induced osteoclastogenesis by human breast cancer cell lines.Increased excretion of collagen crosslinks in irradiated patients indicates destruction of collagen.Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model.The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function.Free circulating tumor DNA as a diagnostic marker for breast cancer.
P2860
Q34122791-57A76E37-7E80-4C2D-A9C0-6DC09330BE2AQ34394082-CAF7698F-3EC2-4452-9092-28DE85943C15Q34524201-306320CC-DF39-457F-9931-920D459CB4D9Q35602668-76FF48AC-BFE0-4844-99EA-C41BD446FB58Q35661057-43161CED-2F3F-4CD4-AC9A-BA6144D46389Q35803713-8A27D87C-D41A-4DED-963B-F5A3FC21A72CQ35894540-A5620950-D20B-4D9E-B93A-D223AED3715DQ36073657-936614C2-4CA7-4F10-A429-836E602D19A0Q36885525-DDFF05DA-A639-4284-8E52-A715DC22BF20Q36971755-18FCAEB6-FDDD-4BD4-95FE-5D768ACC6494Q37155440-05453F72-2378-40CD-84D3-47411D57EBD3Q37408861-4838565F-7454-4058-8353-24940022E42EQ38344166-790D26BD-E464-4C28-A60A-CE17D039B0B5Q39406826-8CEA941F-629B-4200-96A0-D4296BD25ABEQ40301507-9D3DD714-EB36-45D2-93FB-99C60C795B53Q44062508-E46FF1D4-AD18-4D7B-8A49-4BE2A3C2ABD4Q44343595-3E572A99-910D-4AAE-82BD-20688795031EQ46790581-DD52633F-40B9-4A94-A4E4-CEC8C9417EE4
P2860
Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Bisphosphonates and the preven ...... clinical and clinical studies.
@ast
Bisphosphonates and the preven ...... clinical and clinical studies.
@en
type
label
Bisphosphonates and the preven ...... clinical and clinical studies.
@ast
Bisphosphonates and the preven ...... clinical and clinical studies.
@en
prefLabel
Bisphosphonates and the preven ...... clinical and clinical studies.
@ast
Bisphosphonates and the preven ...... clinical and clinical studies.
@en
P2093
P2860
P1433
P1476
Bisphosphonates and the preven ...... clinical and clinical studies.
@en
P2093
P2860
P304
P356
10.1002/1097-0142(20000615)88:12+<3080::AID-CNCR27>3.0.CO;2-W
P407
P433
P577
2000-06-01T00:00:00Z